NEW YORK (GenomeWeb) – Tokai Pharmaceuticals said today it is working with Johns Hopkins University to develop a companion diagnostic for its investigational, castration-resistant prostate cancer (CRPC) drug galeterone.

Under its agreement, Cambridge, Mass.-based Tokai has garnered an exclusive, worldwide license from JHU for "patent applications and know-how" covering a test used to assess the AR-V7 status of prostate cancer patients.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.